NCT05491083View on ClinicalTrials.gov

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid TumorTriple Negative Breast Cancer
Interventions
DRUG

Pembrolizumab & ADG106 (Phase Ib)

"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"

DRUG

Pembrolizumab & ADG106 (Phase II)

"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

Sponsors

Collaborators (1)

Adagene Inc
All Listed Sponsors
collaborator

Adagene Inc

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National University Hospital, Singapore

OTHER